尾崎 行男

Medicine & Life Sciences

1. Myocardial Infarction 100%
2. Stents 83%
3. Acute Coronary Syndrome 78%
4. pitavastatin 70%
5. Percutaneous Coronary Intervention 70%
6. Coronary Artery Disease 66%
7. Hydroxymethylglutaryl-CoA Reductase Inhibitors 62%
8. Computed Tomography Angiography 61%
9. Heart Failure 61%
10. Coronary Angiography 60%
11. Atrial Fibrillation 57%
12. Coronary Vessels 51%
13. Angiography 43%
14. Optical Coherence Tomography 43%
15. Registries 40%
16. Japan 38%
17. Brain Natriuretic Peptide 37%
18. Balloon Angioplasty 35%
19. Pathologic Constriction 31%
20. Atorvastatin 29%
21. Lipids 28%
22. Non-ST Elevated Myocardial Infarction 26%
23. Hemorrhage 26%
24. Therapeutics 25%
25. LDL Cholesterol 24%
26. Chronic Renal Insufficiency 24%
27. Unstable Angina 24%
28. Sirolimus 24%
29. Rivaroxaban 22%
30. ST Elevation Myocardial Infarction 21%
31. iodofiltic acid 20%
32. Eicosapentaenoic Acid 19%
33. Mortality 19%
34. Ergonovine 19%
35. Echocardiography 19%
36. Stroke Volume 18%
37. Myocardial Perfusion Imaging 18%
38. Thrombosis 18%
39. Hospital Mortality 18%
40. Atherosclerotic Plaques 18%
41. Confidence Intervals 18%
42. Multicenter Studies 17%
43. Coronary Stenosis 17%
44. Cardiology 17%
45. Subarachnoid Hemorrhage 17%
46. Angiotensin Receptor Antagonists 16%
47. Incidence 16%
48. Drug-Eluting Stents 16%
49. Anticoagulants 15%
50. Stroke 15%